Geron Corporation (0IV3.L)
USD 1.38
(0.77%)
USD 1.38
(0.77%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -174.78 Million USD | -42.88% |
| 2022 | -134.15 Million USD | -21.0% |
| 2021 | -111.58 Million USD | -48.95% |
| 2020 | -73.92 Million USD | -3.33% |
| 2019 | -67.77 Million USD | -122.87% |
| 2018 | -26.95 Million USD | -16.86% |
| 2017 | -29.17 Million USD | 5.48% |
| 2016 | -30.56 Million USD | -2168.4% |
| 2015 | 803 Thousand USD | 103.96% |
| 2014 | -35.62 Million USD | 0.79% |
| 2013 | -38.05 Million USD | 45.08% |
| 2012 | -67.81 Million USD | 20.16% |
| 2011 | -95.03 Million USD | -99.77% |
| 2010 | -109.67 Million USD | 41.25% |
| 2009 | -68.28 Million USD | -8.23% |
| 2008 | -59.91 Million USD | 14.83% |
| 2007 | -62.83 Million USD | -43.56% |
| 2006 | -47.36 Million USD | -33.53% |
| 2005 | -35.84 Million USD | -408.32% |
| 2004 | -32.23 Million USD | 151.11% |
| 2003 | -26.05 Million USD | 18.74% |
| 2002 | -31.11 Million USD | -66.02% |
| 2001 | -30.64 Million USD | 13.08% |
| 2000 | -21.55 Million USD | -442.21% |
| 1999 | -17.1 Million USD | 146.32% |
| 1998 | -10.9 Million USD | -22.52% |
| 1997 | -9.3 Million USD | 13.28% |
| 1996 | -11 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -68.9 Million USD | -23.13% |
| 2024 Q1 | -55.85 Million USD | -4.59% |
| 2023 Q3 | -47.61 Million USD | -1.41% |
| 2023 Q1 | -36.2 Million USD | 10.9% |
| 2023 Q4 | -54.04 Million USD | -13.52% |
| 2023 Q2 | -46.94 Million USD | -29.69% |
| 2023 FY | - USD | -42.88% |
| 2022 FY | - USD | -21.0% |
| 2022 Q1 | -28.42 Million USD | 7.29% |
| 2022 Q2 | -26.32 Million USD | 7.39% |
| 2022 Q3 | -39.23 Million USD | -49.07% |
| 2022 Q4 | -40.63 Million USD | -3.56% |
| 2021 Q2 | -28.58 Million USD | -6.25% |
| 2021 Q1 | -26.9 Million USD | -17.04% |
| 2021 Q3 | -25.44 Million USD | 10.96% |
| 2021 FY | - USD | -48.95% |
| 2021 Q4 | -30.65 Million USD | -20.46% |
| 2020 Q3 | -19.39 Million USD | -18.31% |
| 2020 Q1 | -16.67 Million USD | 44.43% |
| 2020 FY | - USD | -3.33% |
| 2020 Q2 | -16.39 Million USD | 1.69% |
| 2020 Q4 | -22.98 Million USD | -18.5% |
| 2019 Q3 | -15.96 Million USD | -4.93% |
| 2019 FY | - USD | -122.87% |
| 2019 Q1 | -11.28 Million USD | -2.14% |
| 2019 Q2 | -15.21 Million USD | -34.8% |
| 2019 Q4 | -30 Million USD | -87.98% |
| 2018 Q1 | -7.15 Million USD | 3.49% |
| 2018 Q2 | -7.22 Million USD | -1.05% |
| 2018 Q3 | -6.79 Million USD | 6.03% |
| 2018 Q4 | -11.04 Million USD | -62.7% |
| 2018 FY | - USD | -16.86% |
| 2017 FY | - USD | 5.48% |
| 2017 Q1 | -7.14 Million USD | 15.58% |
| 2017 Q3 | -6.86 Million USD | -7.77% |
| 2017 Q2 | -6.36 Million USD | 10.85% |
| 2017 Q4 | -7.41 Million USD | -8.0% |
| 2016 Q3 | -3.53 Million USD | 58.89% |
| 2016 Q1 | -8.8 Million USD | -4.17% |
| 2016 Q4 | -8.46 Million USD | -139.39% |
| 2016 FY | - USD | -2168.4% |
| 2016 Q2 | -8.59 Million USD | 2.31% |
| 2015 Q1 | -8.9 Million USD | 0.11% |
| 2015 FY | - USD | 103.96% |
| 2015 Q3 | 27.18 Million USD | 424.38% |
| 2015 Q2 | -8.38 Million USD | 5.85% |
| 2015 Q4 | -8.44 Million USD | -131.08% |
| 2014 FY | - USD | 0.79% |
| 2014 Q4 | -8.91 Million USD | 9.22% |
| 2014 Q3 | -9.81 Million USD | -14.81% |
| 2014 Q1 | -8.63 Million USD | 1.11% |
| 2014 Q2 | -8.55 Million USD | 0.96% |
| 2013 Q2 | -7.94 Million USD | 33.22% |
| 2013 Q1 | -11.9 Million USD | 9.59% |
| 2013 FY | - USD | 45.08% |
| 2013 Q4 | -8.73 Million USD | -11.57% |
| 2013 Q3 | -7.82 Million USD | 1.56% |
| 2012 Q2 | -18.48 Million USD | 2.41% |
| 2012 Q3 | -15.83 Million USD | 14.36% |
| 2012 Q4 | -13.16 Million USD | 16.84% |
| 2012 FY | - USD | 20.16% |
| 2012 Q1 | -18.94 Million USD | -7.79% |
| 2011 Q2 | -21.65 Million USD | 11.23% |
| 2011 FY | - USD | -99.77% |
| 2011 Q4 | -17.57 Million USD | 11.35% |
| 2011 Q1 | -24.39 Million USD | -327.29% |
| 2011 Q3 | -19.82 Million USD | 8.45% |
| 2010 Q1 | -16.53 Million USD | 10.18% |
| 2010 FY | - USD | 41.25% |
| 2010 Q4 | 10.73 Million USD | 159.28% |
| 2010 Q3 | -18.1 Million USD | -6.21% |
| 2010 Q2 | -17.04 Million USD | -3.1% |
| 2009 Q4 | -18.4 Million USD | -6.01% |
| 2009 Q2 | -17.1 Million USD | -5.41% |
| 2009 Q1 | -16.22 Million USD | 25.57% |
| 2009 FY | - USD | -8.23% |
| 2009 Q3 | -17.36 Million USD | -1.55% |
| 2008 Q4 | -21.79 Million USD | -25.93% |
| 2008 Q2 | -15.28 Million USD | 2.38% |
| 2008 FY | - USD | 14.83% |
| 2008 Q3 | -17.31 Million USD | -13.29% |
| 2008 Q1 | -15.65 Million USD | -6.83% |
| 2007 Q2 | -16.3 Million USD | 47.23% |
| 2007 Q4 | -14.65 Million USD | -0.91% |
| 2007 FY | - USD | -43.56% |
| 2007 Q1 | -30.88 Million USD | -143.07% |
| 2007 Q3 | -14.52 Million USD | 10.93% |
| 2006 Q4 | -12.7 Million USD | -7.66% |
| 2006 FY | - USD | -33.53% |
| 2006 Q3 | -11.8 Million USD | -6.41% |
| 2006 Q2 | -11.09 Million USD | -9.12% |
| 2006 Q1 | -10.16 Million USD | -4.77% |
| 2005 Q2 | -2.82 Million USD | 69.57% |
| 2005 Q4 | -9.7 Million USD | 20.06% |
| 2005 FY | - USD | -408.32% |
| 2005 Q1 | -9.29 Million USD | -4.27% |
| 2005 Q3 | -12.13 Million USD | -329.06% |
| 2004 Q2 | -7.34 Million USD | -118.38% |
| 2004 Q3 | -8.96 Million USD | -22.01% |
| 2004 Q1 | 39.98 Million USD | 657.68% |
| 2004 FY | - USD | 151.11% |
| 2004 Q4 | -8.91 Million USD | 0.55% |
| 2003 Q3 | -4.22 Million USD | 38.49% |
| 2003 Q1 | -7.01 Million USD | -71.67% |
| 2003 Q2 | -7.64 Million USD | 5.14% |
| 2003 Q4 | -7.17 Million USD | -69.7% |
| 2003 FY | - USD | 18.74% |
| 2002 Q2 | -9.48 Million USD | 16.09% |
| 2002 Q3 | -7.01 Million USD | 23.05% |
| 2002 Q4 | -4.21 Million USD | 39.89% |
| 2002 Q1 | -10.86 Million USD | -126.54% |
| 2002 FY | - USD | -66.02% |
| 2001 Q2 | -7.04 Million USD | 16.96% |
| 2001 FY | - USD | 13.08% |
| 2001 Q4 | -4.79 Million USD | 53.49% |
| 2001 Q3 | -10.31 Million USD | -46.32% |
| 2001 Q1 | -8.48 Million USD | -985.55% |
| 2000 Q1 | -8.58 Million USD | -157.65% |
| 2000 Q4 | -782 Thousand USD | 86.95% |
| 2000 Q3 | -5.99 Million USD | 3.34% |
| 2000 FY | - USD | -442.21% |
| 2000 Q2 | -6.19 Million USD | 7.48% |
| 1999 Q3 | -6.5 Million USD | -134.03% |
| 1999 Q2 | -4.25 Million USD | 554.76% |
| 1999 FY | - USD | 146.32% |
| 1999 Q1 | -3.5 Million USD | -16.67% |
| 1999 Q4 | -2.6 Million USD | 60.0% |
| 1998 Q3 | -3 Million USD | 10.0% |
| 1998 Q4 | -2.9 Million USD | 0.0% |
| 1998 Q2 | -3.1 Million USD | -66.67% |
| 1998 Q1 | -1.9 Million USD | -50.0% |
| 1998 FY | - USD | -22.52% |
| 1997 Q1 | -4.3 Million USD | -15.0% |
| 1997 Q4 | -1.1 Million USD | 33.33% |
| 1997 FY | - USD | 13.28% |
| 1997 Q3 | -1.9 Million USD | 7.69% |
| 1997 Q2 | -2 Million USD | 43.48% |
| 1996 Q2 | -2.5 Million USD | -3.7% |
| 1996 FY | - USD | 0.0% |
| 1996 Q4 | -3.3 Million USD | -21.21% |
| 1996 Q3 | -2.8 Million USD | -17.86% |
| 1996 Q1 | -2.4 Million USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| uniQure N.V. | -253.1 Million USD | 30.944% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 49.407% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -89.817% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 34.292% |
| bluebird bio, Inc. | -167.16 Million USD | -4.559% |
| Cara Therapeutics, Inc. | -117.65 Million USD | -48.561% |
| Imunon, Inc. | -20.78 Million USD | -741.015% |
| Editas Medicine, Inc. | -163.11 Million USD | -7.151% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 105.368% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 115.015% |
| Myriad Genetics, Inc. | -67.8 Million USD | -157.791% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 142.005% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 277.873% |
| Verastem, Inc. | -83.16 Million USD | -110.16% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 98.45% |
| Waters Corporation | 1.02 Billion USD | 117.098% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 101.618% |
| Biogen Inc. | 2.37 Billion USD | 107.353% |
| Nektar Therapeutics | -243.1 Million USD | 28.105% |
| Perrigo Company plc | 646.2 Million USD | 127.048% |
| Dynavax Technologies Corporation | 9.66 Million USD | 1908.214% |
| Illumina, Inc. | -608 Million USD | 71.253% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -293.328% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 61.074% |
| Heron Therapeutics, Inc. | -103.79 Million USD | -68.396% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -368.798% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 156.33% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -99.918% |
| Evolus, Inc. | -41.81 Million USD | -318.039% |
| Adicet Bio, Inc. | -136.53 Million USD | -28.013% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | -98.65% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 103.755% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | -16.437% |
| FibroGen, Inc. | -261.4 Million USD | 33.137% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 110.422% |
| OPKO Health, Inc. | -65.51 Million USD | -166.778% |
| Homology Medicines, Inc. | -47.75 Million USD | -265.99% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 23.382% |
| Exelixis, Inc. | 196.6 Million USD | 188.901% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -73.348% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -213.477% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 65.48% |
| Zoetis Inc. | 3.68 Billion USD | 104.743% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 22.316% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -245.61% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 103.795% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -384.402% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 24.011% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 60.204% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 261.351% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 138.673% |
| Blueprint Medicines Corporation | -474.61 Million USD | 63.174% |
| Insmed Incorporated | -654.73 Million USD | 73.305% |
| TG Therapeutics, Inc. | 26.1 Million USD | 769.663% |
| Incyte Corporation | 919.42 Million USD | 119.01% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 65.41% |